Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06171685 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MMRC Horizon One: RRMM (MMRC-099)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting Site details revised at 13 of 13 sitesv7 Show 1 more changeShow less
    • Site details revised at 13 of 13 sites
  2. Study title shortened, about 5 wordsv6 See this version in full on ClinicalTrials.gov ↗
  3. Eligibility criteria shortened, about 562 words Site details revised at 3 of 13 sitesv5 Show 1 more changeShow less
    • Site details revised at 3 of 13 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Site details revised at 7 of 13 sitesv4
  5. Study sites: 2 to 13 Start date changed from estimate of Nov 30, 2024 to Nov 17, 2024 · Interventions: Investigational Agent (Drug), Teclistamab (Drug) to Teclistamab (Drug), Teclistamab Monotherapy (Drug)v3 Show 2 more changesShow less
    • Start date changed from estimate of Nov 30, 2024 to Nov 17, 2024
    • Interventions: Investigational Agent (Drug), Teclistamab (Drug) to Teclistamab (Drug), Teclistamab Monotherapy (Drug)
  6. Trial status: Not Yet Recruiting to Recruiting Start date: Jul 31, 2024 to Nov 30, 2024 · Study sites: 0 to 2 · Study title expanded, about 2 wordsv2 Show 3 more changesShow less
    • Start date: Jul 31, 2024 to Nov 30, 2024
    • Study sites: 0 to 2
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.
Trial Details
NCT Number NCT06171685
Lead Sponsor Multiple Myeloma Research Consortium
Conditions Relapse Multiple Myeloma, Refractory Multiple Myeloma
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov